An Open-Label, Non-controlled, Non-randomized Sequential Design, Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin in Patients With Advanced Solid Cancers
Phase of Trial: Phase II
Latest Information Update: 27 May 2017
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Necitumumab (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 30 Sep 2016 Results of pooled analysis (N=807) of (I4X-IE-JFCA,JFCB,JFCC, JFCI,JFCJ) published in the Clinical Pharmacokinetics (2016).
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 16 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.